Get the Stockscreener App
7.93
4.07%
0.31
Pre-market:
7.98
0.05
+0.63%
Rxsight Inc stock is traded at $7.93, with a volume of 640.37K.
It is up +4.07% in the last 24 hours and down -0.13% over the past month.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
See More
Previous Close:
$7.62
Open:
$7.71
24h Volume:
640.37K
Relative Volume:
0.68
Market Cap:
$326.05M
Revenue:
$142.09M
Net Income/Loss:
$-35.73M
P/E Ratio:
-9.0298
EPS:
-0.8782
Net Cash Flow:
$-22.20M
1W Performance:
-9.99%
1M Performance:
-0.13%
6M Performance:
-6.38%
1Y Performance:
-70.48%
1-Day Range:
$7.5925
$8.01
1-Week Range:
$7.135
$9.00
52-Week Range:
$6.32
$27.13
Rxsight Inc Stock (RXST) Company Profile
Name
Rxsight Inc
Sector
Industry
Phone
949-521-7822
Address
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.93 | 313.31M | 142.09M | -35.73M | -22.20M | -0.8782 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jul-15-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-25 | Downgrade | Jefferies | Buy → Hold |
| Jul-09-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-09-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-09-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-19-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-15-25 | Initiated | Piper Sandler | Neutral |
| Apr-09-25 | Downgrade | UBS | Buy → Neutral |
| Apr-04-25 | Downgrade | JP Morgan | Overweight → Underweight |
| Apr-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-20-24 | Downgrade | Stifel | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | UBS | Buy |
| Oct-29-24 | Initiated | Jefferies | Buy |
| Aug-20-24 | Reiterated | Needham | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| May-07-24 | Reiterated | BTIG Research | Buy |
| Dec-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Initiated | Morgan Stanley | Overweight |
| Apr-13-23 | Initiated | Oppenheimer | Outperform |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-08-22 | Initiated | Needham | Buy |
View All
Rxsight Inc Stock (RXST) Latest News
Midday Stock Roundup: Evolus, Xponential up - Orange County Business Journal
Forecast Cut: Will RxSight Inc stock go up in YEARJuly 2025 Outlook & High Return Stock Watch Alerts - baoquankhu1.vn
RxSight (RXST) Q4 2025 Earnings Call Transcript - AOL.com
RxSight (RXST) CCO gains 6,261 shares, withholds 2,580 for taxes - Stock Titan
RXST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Short Interest in RxSight, Inc. (NASDAQ:RXST) Expands By 29.3% - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2026-03-01 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
Artisan Partners Limited Partnership Cuts Position in RxSight, Inc. $RXST - MarketBeat
RXST Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
RxSight, Inc. (RXST) Investor Outlook: Exploring a 28% Potential Upside in the Medical Devices Sector - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Q4 2025 Earnings Call Transcript - Insider Monkey
RxSight Reports Fourth Quarter and Fiscal Year Financial Results - VisionMonday.com
Responsive Playbooks and the RXST Inflection - Stock Traders Daily
Needham reiterates Buy on RxSight stock, keeps $13 target By Investing.com - Investing.com Australia
What 5 Analyst Ratings Have To Say About RxSight - Benzinga
UBS Increases Price Target for RXST to $9.00 While Maintaining N - GuruFocus
RxSight (NASDAQ:RXST) Given New $9.00 Price Target at UBS Group - MarketBeat
RXST: Piper Sandler Lowers Price Target to $10.00, Maintains Neu - GuruFocus
RxSight (NASDAQ:RXST) Price Target Lowered to $10.00 at Piper Sandler - MarketBeat
UBS Adjusts Price Target on RxSight to $9 From $8, Maintains Neutral Rating - marketscreener.com
RxSight, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
RxSight Q4 Earnings Call Highlights - MarketBeat
RxSight (NASDAQ:RXST) Issues Earnings Results - MarketBeat
RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations - Bitget
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts - Investing.com
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
RXSIGHT INC (NASDAQ:RXST) Reports Q4 Beat but Cautious 2026 Outlook Weighs on Shares - ChartMill
Earnings call transcript: RxSight Q4 2025 beats EPS, revenue forecasts By Investing.com - Investing.com South Africa
RxSight, Inc. (RXST) Tops Q4 EPS by 32c - StreetInsider
RxSight (RXST) Releases Q4 2025 Earnings: Revenue Down but Beats Estimates; Loss Narrows, EPS Beats - Quiver Quantitative
RxSight, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance - The Manila Times
RxSight (RXST) grows LAL volume but posts wider 2025 loss, soft 2026 outlook - Stock Titan
RxSight, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Earnings Update: Will RxSight Inc face regulatory challenges2025 Year in Review & Low Drawdown Trading Strategies - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect - Stockhouse
Earnings To Watch: RxSight Inc (RXST) Reports Q4 2025 Result - GuruFocus
Analyst Calls: Can ProQR Therapeutics NV withstand a market correctionBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
2026-02-22 | Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Stockholders to Inquire about Securities Investigation | NDAQ:RXST | Press Release - Stockhouse
RxSight, Inc. (RXST) initiated at market perform as firm seeks sales reacceleration - MSN
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Senseonics Holdings (SENS) and Novo Nordisk (NVO) - The Globe and Mail
RxSight, Inc. (RXST) Stock Analysis: A Closer Look At The 23.68% Potential Upside - DirectorsTalk Interviews
RxSight, Inc. (NASDAQ:RXST) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Will RxSight Inc. benefit from AI trendsWeekly Trend Report & AI Enhanced Trading Signals - mfd.ru
Will RxSight Inc. outperform tech stocksJuly 2025 Action & Entry Point Confirmation Alerts - mfd.ru
Can RxSight Inc. deliver consistent EPS growth2025 Retail Activity & Safe Swing Trade Setup Alerts - mfd.ru
Earnings Preview: Teleflex (TFX) Q4 Earnings Expected to Decline - Finviz
2026-02-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Investors to Learn More About the Investigation | NDAQ:RXST | Press Release - Stockhouse
Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline - Finviz
Rxsight Inc Stock (RXST) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):